

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3321484

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	ALLOZYNE, INC.	05/06/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	MEDIMMUNE LIMITED	
<b>Street Address:</b>	MILSTEIN BUILDING, GRANATA PARK	
<b>City:</b>	CAMBRIDGE	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	CB21 6GH	
<b>PROPERTY NUMBERS Total: 3</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	61705116	
<b>Application Number:</b>	61862495	
<b>PCT Number:</b>	EP2013069888	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(814) 474-2303	
<b>Email:</b>	mpytel@glancelaw.com	
<b>Correspondent Name:</b>	GLANCE LAW GROUP PC	
<b>Address Line 1:</b>	7200 VAN CAMP ROAD	
<b>Address Line 4:</b>	GIRARD, PENNSYLVANIA 16417	
<b>ATTORNEY DOCKET NUMBER:</b>	304.0038USWO	
<b>NAME OF SUBMITTER:</b>	NICHOLAS LINDGREN	
<b>SIGNATURE:</b>	/Nicholas Lindgren/	
<b>DATE SIGNED:</b>	04/22/2015	
<b>Total Attachments: 9</b>		
source=304-0038USWO_Allozyne-MedImmune#page1.tif		
source=304-0038USWO_Allozyne-MedImmune#page2.tif		
source=304-0038USWO_Allozyne-MedImmune#page3.tif		
source=304-0038USWO_Allozyne-MedImmune#page4.tif		

source=304-0038USWO\_Allozyne-MedImmune#page5.tif  
source=304-0038USWO\_Allozyne-MedImmune#page6.tif  
source=304-0038USWO\_Allozyne-MedImmune#page7.tif  
source=304-0038USWO\_Allozyne-MedImmune#page8.tif  
source=304-0038USWO\_Allozyne-MedImmune#page9.tif

## PATENT ASSIGNMENT

Pursuant to that certain Asset Purchase Agreement (the "PURCHASE AGREEMENT") of even date herewith by and between Allozyne, Inc. a Delaware corporation, having a place of business at 1600 Fairview Avenue East, Suite 300, Seattle, WA 98102 ("ASSIGNOR") and MedImmune Limited, having a place of business at Milstein Building, Grant Park, Cambridge CB21 6GH, United Kingdom ("ASSIGNEE"), for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR has sold, assigned, and transferred and does hereby sell, assign, and transfer to ASSIGNEE, for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the patents and patent applications set forth on Exhibit A hereto ("PATENT RIGHTS"); and

2. The entire worldwide right, title, and interest in and to: (a) the PATENT RIGHTS, including any right of priority; (b) any divisional, continuation, substitute, renewal, reissue, and other related applications thereto which have been or may be filed in the United States or elsewhere in the world; (c) any patents which may be granted on the applications set forth in (a) and (b) above; and (d) the right to sue in its own name and to recover for past infringement of any or all of any applications or patents issuing therefrom.

ASSIGNOR agrees to do the following, as reasonably requested in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER of the above-identified Patent; and (3) generally do all lawful acts that ASSIGNEE reasonably requires for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER of the above mentioned Patent.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

Duly Authorized Representative of ASSIGNOR

  
Meenu Chhabra, President and CEO

Date of Signature

May 6, 2014

Duly Authorized Representative of ASSIGNOR

  
Steven Gillis, Director and Chairman

*Handwritten signature*  
3/30/15

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED


2/3/2015

✓ 3/20/5

✓ 3/24/11

*[Handwritten signature]*  
*5/20/10*



  
3/5/14

**Unpublished Assigned Intellectual Property**

Allozyme (AZ) ref	Territory	Application Number	Filing Date	Title	Inventors	Owner	Status
P420USp	US	63/705,116	24 Sept 2012	Cell Lines	Marelli, VanBrunt, Grabstein	Allozyme	Converted into PCT

*[Handwritten signature]*  
3/20/12

Allosyne (AZ) ref	Territory	Application Number	Filing Date	Title	Inventors	Owner	Status
P425USp	US	61/793,435	15 March 2013	Cell lines	Marelli, VanBrunt, Grabstein	Allosyne	Abandoned
P428USp	US	61/862,485	5 August 2013	Cell lines	Marelli, VanBrunt, Grabstein	Allosyne	Converted into PCT
P429PCT		PCT/EP2013/069887	24 September 2013	Cell lines	Marelli, VanBrunt, Grabstein	Allosyne	Pending Published March 2014
P430PCT		PCT/EP2013/069888	24 September 2013	Aminoacid derivatives	Marelli, VanBrunt, Grabstein	Allosyne	Pending Published March 2014

  
 3/20/14